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Abstract
During the extended clinically latent period associated with Human Immunodeficiency Virus (HIV)
infection the virus itself is far from latent. This phase of infection generally comes to an end with
the development of symptomatic illness. Understanding the factors affecting disease progression
can aid treatment commencement and therapeutic monitoring decisions. An example of this is the
clear utility of CD4+ T-cell count and HIV-RNA for disease stage and progression assessment.
Elements of the immune response such as the diversity of HIV-specific cytotoxic lymphocyte
responses and cell-surface CD38 expression correlate significantly with the control of viral
replication. However, the relationship between soluble markers of immune activation and disease
progression remains inconclusive. In patients on treatment, sustained virological rebound to >10
000 copies/mL is associated with poor clinical outcome. However, the same is not true of transient
elevations of HIV RNA (blips). Another virological factor, drug resistance, is becoming a growing
problem around the globe and monitoring must play a part in the surveillance and control of the
epidemic worldwide. The links between chemokine receptor tropism and rate of disease
progression remain uncertain and the clinical utility of monitoring viral strain is yet to be
determined. The large number of confounding factors has made investigation of the roles of race
and viral subtype difficult, and further research is needed to elucidate their significance.
Host factors such as age, HLA and CYP polymorphisms and psychosocial factors remain important,
though often unalterable, predictors of disease progression. Although gender and mode of
transmission have a lesser role in disease progression, they may impact other markers such as viral
load. Finally, readily measurable markers of disease such as total lymphocyte count, haemoglobin,
body mass index and delayed type hypersensitivity may come into favour as ART becomes
increasingly available in resource-limited parts of the world. The influence of these, and other
factors, on the clinical progression of HIV infection are reviewed in detail, both preceding and
following treatment initiation.
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Review
Throughout the clinically latent period associated with
Human Immunodeficiency Virus (HIV) infection the
virus continues to actively replicate, usually resulting in
symptomatic illness [1-3]. Highly variable disease pro-
gression rates between individuals are well-recognised,
with progression categorised as rapid, typical or interme-
diate and late or long-term non-progression [1,4]. The
majority of infected individuals (70–80%) experience
intermediate disease progression in which they have HIV-
RNA rise, CD4+ T-cell decline and development of AIDS-
related illnesses within 6–10 years of acquiring HIV. Ten
to 15% are rapid progressors who have a fast CD4+ T-cell
decline and occurrence of AIDS-related events within a
few years after infection. The late progressors (5%), can
remain healthy without significant changes in CD4 count
or HIV-RNA for over 10 years [4].
While Figure 1[5] demonstrates the existence of a relation-
ship between high plasma HIV-RNA, low peripheral
CD4+ T-cell count and rapidity of disease progression,
many of the determinants of this variation in progression
are only partially understood. Knowledge of prognostic
determinants is important to guide patient management
and treatment. Much research has focussed on many dif-
ferent facets of HIV pathogenesis and possible predictive
factors, covering immunological, virological and host
genetic aspects of disease. Current therapeutic guidelines
take many of these into account but their individual sig-
nificance warrants review [6].
Immunological factors
T-cell count and function
CD4+ T-cells
CD4+ T-cells are fundamental to the development of spe-
cific immune responses to infection, particularly intracel-
lular pathogens. As the primary target of HIV, their
depletion severely limits the host response capacity. HIV
largely infects activated cells, causing the activated T-cells
directed against the virus to be at greatest risk of infection
[7]. The ability of the immune system to mount a specific
response against HIV is a key factor in the subsequent dis-
ease course [8]. Long-term non-progressors appear to have
better lymphoproliferative responses to HIV-specific anti-
gens than those with more rapid progression [8].
The CD4+ T-cell count is the most significant predictor of
disease progression and survival [9-15], and the US
Department of Health and Human Services (DHHS) ART
treatment guidelines recommends treatment commence-
ment be based on CD4+ T-cell count in preference to any
other single marker [6]. Table 1 shows the results of the
CASCADE collaborationi  (see Appendix 1 for details)
analysis of an international cohort of 3226 ART-naïve
individuals with estimable dates of seroconversion. Each
CD4 count was considered to hold predictive value for no
more than the subsequent 6 month period, with individ-
ual patients contributing multiple 6 month periods of fol-
low up [10]. Lower CD4 counts are associated with greater
risk of disease progression. CD4 counts from 350–500
cells/mm3 are associated with risks of ≤5% across all age
and HIV-RNA strata, while the risk of progression to AIDS
increases substantially at CD4 counts <350 cells/mm3, the
greatest risk increase occurring as CD4 counts fall below
200 cells/mm3. The risk of disease progression at 200
cells/mm3, the threshold for ART initiation in resource-
limited settings, is generally double the risk at 350 cells/
mm3, the treatment threshold in resource-rich countries
[10].
Use of the CD4 count as a means of monitoring ART effi-
cacy is well established [6,16]. In particular, measurement
of the early response in the first six months of therapy has
strong predictive value for future immunological progres-
sion [17,18]. Baseline CD4 count is predictive of virolog-
ical failure, Van Leth et al. [19] finding a statistically
significant correlation between a baseline CD4 count of
General pattern of the natural history of HIV-RNA levels and  CD4 counts at three rates of disease progression [5] (Repro- duced from Figure 1, HIV InSite Knowledge Base, with per- mission) Figure 1
General pattern of the natural history of HIV-RNA levels and 
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<200 cell/mm3 and HIV-RNA >50 copies/mL at week 48
of therapy. Figure 2 shows the importance of baseline
CD4 count as a predictor of disease progression; each stra-
tum of CD4 count <200 cell/mm3 at time of HAART initi-
ation being associated with an increasingly worse
prognosis [20]. Immunological recovery is largely
dependent on baseline CD4 count and thus the timing of
ART initiation is important in order to maximise the
CD4+ T-cell response to therapy [20].
It is important to note that within-patient variability in
CD4+ T-cell quantification can occur and so care must be
taken to ensure measurements are consistently performed
by the same method for each patient [9].
CD8 T-lymphocyte function
The influence of CD8+ T-lymphocyte function on HIV dis-
ease progression is of considerable interest as cytotoxic T-
lymphocytes (CTLs) are the main effector cells of the spe-
cific cellular immune response. Activated by CD4+ T-
helper cells, anti-HIV specific CD8+ T-cells have a crucial
role to play in the control of viremia [21], increasing in
response to ongoing viral replication [22]. Further, the
diversity of HIV-specific CTL responses correlates with the
control of viral replication and CD4 count, indicating the
need for a response to a broad range of antigens to achieve
a maximum effect [23,24]. Low absolute numbers of HIV-
specific CD8+ T-cells correlate with poor survival out-
comes in both ART-naïve and experienced patients, pro-
viding additional evidence for the significance of the CTL
response [23,25,26].
Immune activation
Chronic immune activation is a characteristic of HIV dis-
ease progression. Immune-activation-driven apoptosis of
CD4+ cells, more than a direct virological pathogenic
effect, is responsible for the decline in CD4+ T-lym-
phocytes seen in HIV infection [27]. HIV triggers polyclo-
nal B cell activation, increased T cell turnover, production
of proinflammatory cytokines and increased numbers of
Table 1: Predicted 6 month risk of AIDS according to age, current CD4+ cell count and viral load, based on a Poisson regression 
model
Viral load (copies/mL) Predicted risk (%) at current CD4 count (× 106 cells/L)
Age 50 100 150 200 250 300 350 400 450 500
25 years
3000 6.8 3.7 2.3 1.6 1.1 0.8 0.6 0.5 0.4 0.3
10 000 9 . 65 . 33 . 42 . 31.6 1.2 0.9 0.7 0.5 0.4
30 000 13.3 7.4 4.7 3.2 2.2 1.6 1.2 0.9 0.7 0.6
100 000 18.6 10.6 6.7 4.6 3.2 2.4 1.8 1.4 1.1 0.8
300 000 25.1 14.5 9.3 6.3 4.5 3.3 2.5 1.9 1.5 1.2
35 years
3000 8 . 54 . 73 . 02 . 01.4 1.0 0.8 0.6 0.5 0.4
10 000 12.1 6.7 4.3 2.9 2.0 1.5 1.1 0.9 0.7 0.5
30 000 16.6 9.3 5.9 4.0 2.8 2.1 1.6 1.2 0.9 0.7
100 000 23.1 13.2 8.5 5.8 4.1 3.0 2.3 1.7 1.3 1.1
300 000 30.8 18.0 11.7 8.0 5.7 4.2 3.1 2.4 1.9 1.5
45 years
3000 10.7 5.9 3.7 2.5 1.8 1.3 1.0 0.7 0.6 0.5
10 000 15.1 8.5 5.4 3.6 2.6 1.9 1.4 1.1 0.8 0.7
30 000 20.6 11.7 7.5 5.1 3.6 2.6 2.0 1.5 1.2 0.9
100 000 28.4 16.5 10.6 7.3 5.2 3.8 2.9 2.2 1.7 1.3
300 000 37.4 22.4 14.6 10.1 7 . 25 . 34 . 03 . 12 . 41.9
55 years
3000 13.4 7.5 4.7 3.2 2.3 1.7 1.2 0.9 0.7 0.6
10 000 18.8 10.7 6.8 4.6 3.3 2.4 1.8 1.4 1.1 0.8
30 000 25.4 14.6 9.4 6.4 4.6 3.3 2.5 1.9 1.5 1.2
100 000 34.6 20.5 13.3 9.2 6.5 4.8 3.6 2.8 2.2 1.7
300 000 44.8 27.5 18.2 12.6 9 . 16 . 75 . 03 . 93 . 02 . 4
<2%, risk 2–9.9%, risk 10–19.9%, risk ≥20%
This table is reproduced from Table 4 in [10]AIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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activated T cells [28]. CD4+ T cells that express activation
markers such as CD69, CD25, and MHC class II are a
prime target for HIV infection and a source of active HIV
replication. Increased numbers of these activated T cells
correlate with HIV disease progression [29-31]. Another
important surface marker of cell activation is CD38. In
HIV negative individuals, CD38 is expressed in relatively
greater numbers by naïve lymphocytes, while in HIV
infection, memory T-cells, particularly CD8+ memory T-
cells, express the largest quantities of CD38 [32,33].
CD8+CD38+T-cell levels correlate strongly with HIV-RNA
levels, decreasing with ART-induced virological suppres-
sion and increasing with transient viremia, suggesting that
continuously high levels of CD38+ cells may be an indica-
tor of ongoing viral replication [32-35]. Indeed, HIV rep-
lication has been nominated the main driving force
behind CD8+ T-cell activation [32,33]. Similar to the sta-
bilization of HIV-RNA levels following initial infection,
an immune activation "set point" has also been described
and shown to have prognostic value [36].
Despite the strength of the relationship with HIV-RNA,
the search for a clear association between CD8+ T-cell acti-
vation and CD4 count has resulted in conflicting findings
[32,33,35,37]. In contrast, CD4+ T-cell activation has a
considerable influence on CD4+ T-cell decline [27,34,35].
One prospective study of 102 seroconverters has found
that CD8+CD38+ proportions lose their prognostic signif-
icance over time and only elevated CD4+CD38+ percent-
age is associated with clinical deterioration at 5 years
follow up [27]. The clinical value of monitoring CD38
expression is yet to be clarified, however, there is no doubt
that disease progression is related to both CD4+ and
CD8+ T-cell activation as indicated by expression of
CD38.
A switch from T-Helper Type 1 (TH1) to T-Helper Type 2
(TH2) cytokine response is seen in HIV-related immune
dysfunction and is associated with HIV disease progres-
sion. TH1 cytokines such as interleukin (IL)-2, IL-12, IL-
18 and interferon-γ promote strong cellular responses and
early HIV viremic control while TH2 cytokines, predomi-
nantly modulated by IL-1β, IL-4, IL-6, IL-10 and tumor
necrosis factor-α (TNF-α), promote HIV viral replication
and dampen cellular response to HIV [8,38]. HIV-positive
individuals have high plasma IL-10 levels, reduced pro-
duction of IL-12 and poor proliferation of IL-2 producing
CD4+ central memory T-cells [30,39,40]. Levels of pro-
inflammatory cytokines such as TNF-α are also increased,
causing CD8+ T-cell apoptosis [1,40].
Soluble markers of immunological activity have been the
focus of many studies over the years in the hope that they
will show utility as prognostic indicators. Unfortunately,
the product of these endeavours is a large number of stud-
ies with apparently conflicting results, some studies link-
ing elevated levels of these markers with more rapid
disease progression [41-46], and others finding no corre-
lation [46-48]. Factors investigated include neopterin [41-
43,45,46,48],  β2-microglobulin [42,46-48], tumour
necrosis factor type II receptor [41,46], tumour necrosis
factor receptor 75 [45], endogenous interferon [43] and
tumour necrosis factor-α [25]. The lack of specificity of
these markers for HIV infection appears to curtail their
utility. Current treatment guidelines make no mention of
their use for either disease or therapeutic monitoring
[6,49,50]. As the immune response to HIV is clarified with
further research, the utility of monitoring these immune
modulators may become more apparent.
Virological factors
HIV-RNA
The value of HIV-RNA quantification as a prognostic
marker has long been established [6,51,52]. An approxi-
mately inverse relationship to the CD4+ T-cell count and
survival time has been observed in around 80% of
patients [53,54]. Higher HIV-RNA levels are associated
with more rapid decline of CD4+ T-cells, assisting predic-
tion of the rate of CD4 count decline and disease progres-
sion. However, once the CD4 count is very low (<50–100
cells/mm3), the disease progression risk is so great that
HIV-RNA levels add little prognostic information [25,54-
56]. The correlation between CD4 count and disease pro-
gression seen clearly in Table 1 has already been described
[10]. Further highlighting the risk of AIDS in those with
CD4 counts of 200–350 cell/mm3 (the current threshold
for ART initiation), a four-fold risk increase can be seen
between those with a HIV-RNA of 3000 copies/mL and
those with ≥300 000 copies/mL, even within the same age
bracket. Additionally, there is a considerable increase in
risk of disease progression in those with HIV-RNA >100
000 copies/mL across all age and CD4 strata.
Higher baseline HIV-RNA levels in early infection have
been associated with faster CD4+ T-cell decline over the
Kaplan Meier plots of the probability of progression to AIDS  or death according to baseline CD4 count [20] (reproduced  with permission) Figure 2
Kaplan Meier plots of the probability of progression to AIDS 
or death according to baseline CD4 count [20] (reproduced 
with permission).AIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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first two years of infection [15,57]. Research has suggested
that HIV-RNA levels at later time points are better indica-
tors of long term disease progression than levels at sero-
conversion, with the viral load reaching a stable mean or
'set point' around one year after infection [4,12,52,58,59].
Indicative of the efficiency of immunological control of
viral replication, this set point is strongly associated with
the rate of disease progression as can be inferred from Fig-
ure 1[1,52,59-62]. Desquilbet et al. [63] studied the effect
of early ART on the virological set point by starting treat-
ment during Primary HIV Infection (PHI) and then ceas-
ing it soon after. They found the virological set point was
mainly determined by pre-treatment viral load, early treat-
ment having minimal reducing effect.
Treatment response has been strongly linked to the base-
line HIV-RNA level; Van Leth et al. [19] finding that
patients with a HIV-RNA >100 000 copies/mL were
almost 1.5 times more likely to experience virological fail-
ure (HIV-RNA >50 copies/mL) after 48 weeks of treatment
than those with HIV-RNA <100 000 copies/mL.
An analysis of a subgroup (6814 participants) of the
EuroSIDA study cohort verified that clinical outcome cor-
relates strongly with most recent CD4+ T-cell or HIV RNA
level, regardless of ART regimen used. In particular, it is
worth noting that those with CD4 count ≤350 cells/mm3
were at increased risk of AIDS or death than higher CD4
counts (rate ratio ≥3.39 vs ≤1.57), while the risk of these
outcomes was substantially lower at HIV-RNA <500 cop-
ies/mL compared to >50 000 copies/mL (rate ratio 0.22 vs
0.61) [64]. These findings support the continued use of
HIV-RNA and CD4 count as markers of disease progres-
sion on any HAART regimen [6,51,65].
There is no doubt that monitoring viral load is critical to
assessing the efficacy of ART [65-68]. Findings from mul-
tiple studies reinforce the association between greater
virological suppression and sustained virological
response to ART [6,50]. Guidelines define virological fail-
ure as either a failure to achieve an undetectable HIV-RNA
(<50 copies/mL) after 6 months or a sustained HIV-RNA
>50 copies/mL or >400 copies/mL following suppression
below this level [6]. A greater than threefold increase in
viral load has been associated with increased risk of clini-
cal deterioration and so this value is recommended to
guide therapeutic regimen change in the developed world
[69,70]. Several studies have shown a significant correla-
tion between HIV-RNA >10 000 copies/mL and increased
mortality and morbidity, and therapeutic switching
should occur prior to this point [49]. The World Health
Organisation recommends that this level be considered
the definition of virological failure in resource limited set-
tings [49].
Some patients experience intermittent episodes of low-
level viremia followed by re-suppression below detectable
levels, known as "blips". A very detailed study by Nettles
et al. [71] defined a typical blip as lasting about 2.5 days,
of low magnitude (79 copies/ml) and requiring no
change in therapy to return to <50 copies/ml. Havlir et al.
[72] and Martinez et al. [73] demonstrated that there was
no association between intermittent low-level viremia
and virological failure. Intermittent viremia does not
appear to be a significant risk factor for disease progres-
sion. Nevertheless, it must be distinguished from true
virological failure, which is consistently elevated HIV-
RNA, as defined above. Continued follow up is essential.
Even in patients achieving apparently undetectable HIV-
RNA levels, the HIV virus persists through the infection of
memory T-cells [74,75]. This 'viral reservoir' has an
extremely long half life and remains remarkably stable
even in prolonged virological suppression [74,76,77].
Responsible for the failure of ART to eradicate infection,
regardless of therapy efficacy, it may also contribute to the
'blips' described above [76]. Like intermittent viremia, its
effect on disease progression appears trivial, being mainly
of therapeutic importance [78,79]. However, as the long-
term clinical outcomes of viral resistance and sub-detec-
tion viral replication become clearer, its significance may
increase [15].
Resistance mutations
Drug resistance is a strong predictor of virological failure
after HAART, with a clear relationship seen between the
number of mutations and virological outcome [56,80-
84]. Hence maximal suppression of viral replication, with
the parallel effect of preventing the development of resist-
ance, is essential to optimise both response to treatment
and improvement in disease progression [85,86].
The transmission of resistant virus is a serious reality, with
implications for the efficacy of initial regimens in ART
naïve patients. Prevalence of resistance mutations
amongst seroconverters varies according to geographic
location, with inter-country prevalence varying from 3–
26%. This reinforces the need to gain local data, especially
as resistance increases with increasing HAART use [87]. In
the USA, the prevalence of primary (transmitted) resist-
ance was 24.1% in 2003–2004, an almost two-fold
increase from the 13.2% prevalence recorded in 1995–
1998 [88]. European prevalence for 2001–2002 was
10.4%, which, although lower than the US figures,
remains quite high [86,87]. Pre-treatment resistance test-
ing has been shown to reduce the risk of virological failure
in patients with primary drug resistance [6,50]. The DHHS
guidelines suggest that pre-treatment resistance testing in
ART naïve patients may be considered if the risk of resist-
ance is high (ie: population prevalence ≥5%) while theAIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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British HIV Association (BHIVA) recommends testing for
transmitted resistance in all newly diagnosed patients and
prior to initiating ART in chronically infected patients
[49]. In resource-limited settings, resistance testing may
not be readily available; however, in such locations, pri-
mary resistance is likely to be rare, and need for pre-treat-
ment resistance testing is lower [89]. An exception to this
rule is the case of child-bearing women who have received
intrapartum nevirapine, in whom poorer virological
responses to post-partum nevirapine based regimens have
been seen (49% vs 68% achieved HIV-RNA <50 copies/
mL at 6 months) [49,89]. Regardless of the setting, there
is a need for surveillance of local drug resistance preva-
lence [1,2,90].
Chemokine receptor tropism
CCR5 and CXCR4 chemokine receptors act as co-receptors
for HIV virions. Proportionately greater tropism for one or
the other of these receptors has been associated with dif-
ferent rates of disease progression. Slowly progressing
phases of infection are associated with predominance of
the "R5 virus strains" that ligate the CCR5 receptor,
mainly present on activated immune cell surfaces (includ-
ing macrophages). "X4 strains" showing tropism for
CXCR4, expressed by naïve or resting T-cells, and dual-
tropic R5X4 strains, increase proportionately in the later
stages of disease and are associated with more rapid clini-
cal and immunological deterioration [1,2,90]. 'X4' strains
have been associated with greater immune activation, sug-
gesting a possible mechanism for their effects on disease
progression [27]. Patients with predominantly X4 strains
have been found to have lower CD4 counts, but correla-
tions with viral load have been inconsistent [90-92].
Some host genetic phenotypes namely CCR5-∆32 and
SDF-1'A, affect R5 strain binding and are associated with
delayed disease progression [93-95].
It is evident that even under effective HAART suppression
[96], the predominant viral strain can change from R5 to
X4 [90,92,97]. Additionally, about 50% of triple therapy
experienced patients have been found to harbour X4
strains, a far greater proportion than the 18.2% seen in an
ART naïve population [98]. The evidence for a difference
in survival between those on HAART with X4 strains and
those with R5 strains is difficult to interpret. Brumme et al.
[98] suggested that a group of patients with the 11/25
envelope sequence (a highly specific predictor of the pres-
ence of X4 strains) had higher mortality and poorer
immunological response to HAART despite similar viro-
logical responses to those without the 11/25 sequence. In
contrast, a later study indicated that after adjustment for
baseline characteristics, X4 strains were not associated
with a difference in survival or response to HAART [99].
As can be seen, the effects of chemokine receptor tropism
remain controversial and as yet, there is no clear evidence
that monitoring or measuring these parameters will be
useful clinically.
Viral subtype and race
Complicating the assessment of the effect of viral subtype
on disease progression are the potential confounders such
as race, prevalence of various opportunistic infections and
access to health care. Subtype C affects 50% of people
with HIV and is seen mostly in Southern and Eastern
Africa, India and China. Subtype D is found in East Africa
and Subtype CRF_01 AE is seen mainly in Thailand. Cau-
casians are predominantly infected by subtype B, seen in
12% of the global HIV infected population [99]. The
majority of research on all aspects of HIV has been per-
formed amongst subtype B-affected individuals. The
implications for treatment practice are obvious should
differences in viral pathogenicity or disease progression
exist between subtypes [99,100].
Rangsin et al. [100] noted median survival times in young
Thai men (Type E 97%) of only 7.4 years, significantly
shorter than the 11.0 years reported by the mainly Cauca-
sian CASCADE cohort (Type B ≥50%). Hu et al. [101]
found differences in early viral load between those with
Type E (n = 103) when compared to Type B (n = 27) in
Thai injecting drug users. Kaleebu et al. [102] studied a
large cohort in Uganda, providing the strongest evidence
for a difference in survival between A and D subtypes.
However, analysis of a small cohort in Sweden reported
no difference in survival rates between subtypes A-D
[103]. Only Rangsin et al. [100] and Hu et al. [101] stud-
ied cohorts with estimable seroconversion dates.
It is difficult to control for the multiple potential con-
founding factors in research measuring the influence of
subtype on disease progression. Geretti [99] remarked
that the evidence for survival and disease progression rate
differences between subtypes is currently inadequate to
draw any definitive conclusions. Ongoing research is
essential not only to determine the effect of subtype on
disease progression but also to evaluate response to ther-
apy.
Many of the confounding factors affecting subtype inves-
tigation also confound research into the effect of race on
disease progression. Studies with clinical endpoints have
found no significant relationship between race and dis-
ease progression [104,105], while another study of clini-
cal response to HAART suggested disease progression
appears to correlate more strongly with other factors (eg:
depression, drug toxicity) than with race per se [106]. In
support of this, data from the TAHOD databaseii (see
Appendix 1 for details) suggests that responses to HAART
among Asians are comparable to those seen in other races
[11]. Evidence for racial variation in viral loads and CD4AIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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counts has not been consistent and confounders have
been difficult to exclude [107-109]. Morgan et al. [110]
reported a median survival time of 9.8 years amongst HIV
infected Ugandans which does not differ greatly from the
11.0 years reported by the mainly Caucasian CASCADE
cohort. Race as an independent factor does not appear to
play a part in the rate of disease progression independ-
ently of confounders such as psychosocial factors, access
to care and genetically driven response to therapy.
Host genetics
An understanding of the effect of host genetics on disease
susceptibility and progression has significant implications
for the development of therapies and vaccines [95]. Host
genetics impact HIV infection at two main points: (i) cell-
virion fusion, mediated primarily by the chemokine
receptors CXCR4 and CCR5 and their natural ligands, and
(ii) the host immune response, mediated by Human Leu-
kocyte Antigen (HLA) molecules [95,111].
Polymorphisms of the genes controlling these two path-
ways have been extensively studied and multiple genetic
alleles that have been found to correlate with either
delayed or accelerated disease progression [95,111,112].
HLA molecules provide the mechanism by which the
immune system generates a specific response to a patho-
gen. As has been described earlier, the diversity of HIV-
specific immune responses plays a crucial role in contain-
ment of the virus and it is HLA molecules that control that
diversity. Thus, HLA polymorphisms should affect disease
progression. Investigation of the effect of specific alleles
has found that heterozygosity of any MHC Class I HLA
alleles appears to delay progression, while rapid progres-
sion has been associated with some alleles in particular,
for example, HLA-B35 and Cω4[95]. The HLA-B57 allele,
present in 11% of the US population and around 10% of
HIV-positive individuals, has been linked to long-term
non-progression, a lower viral set-point and fewer symp-
toms of primary HIV infection [95,112].
In addition to the effect of genetic polymorphisms on the
natural history of infection, host genetic profile can influ-
ence the response to HAART [113]. In Australia, the pres-
ence of the HLA-B5701 allele accounts for nearly 90% of
patients with abacavir hypersensitivity. Drug clearance
also varies significantly between racial groups due to
genetic variations in CYP enzyme isoforms [114]. For
example, polymorphisms of CYP2B6 occurring more fre-
quently in people of African origin are associated with
three-fold greater plasma efavirenz concentrations, lead-
ing to a greater incidence of central nervous system toxic-
ity amongst this group [115]. Potential outcomes of such
phenomena include treatment discontinuation in the case
of toxicity or hypersensitivity and drug resistance when
medications are ceased simultaneously causing mono-
therapy of the drug with the prolonged half life [114].
Genetic screening in order to guide choice of therapy is
already underway in Australia for HLA-B57 alleles related
to abacavir hypersensitivity [114]. Studies of host genetics
appear likely to significantly influence the clinical man-
agement of HIV in the future.
Other host factors
Studies of many of these factors usually assume equality
of access to care for members of the study population. A
survey of people living with AIDS in New York city found
that female gender, older age, non-Caucasian race and
transmission via injecting drug use or heterosexual inter-
course were all associated with significantly higher mor-
tality. This most likely reflects the poorer access to health
care and other sociological disparities experienced by
these groups [116].
Age
Age at seroconversion has repeatedly been found to have
considerable impact on the future progression of disease.
Concurring with earlier studies, the CASCADE collabora-
tion [62] found a considerable age effect correlating with
CD4 count and HIV-RNA, across all exposure categories,
CD4 count and HIV-RNA strata in an analysis of multiple
international seroconversion cohorts, reinforcing these
findings again recently [10,117,118]. Table 1 clearly dem-
onstrates the importance of stratification by age, CD4
count and HIV-RNA as predictive of the short term risk of
AIDS. There is a clear relationship between increasing risk
with increasing age. For example, a 25 year old with a CD4
count of 200 and HIV-RNA level of 3000 has one third the
risk of disease progression when compared to a 55 year
old. This raises the issue of whether or not older patients
should be treated at higher CD4+ T-cell counts [10].
Older age is associated with lower CD4 counts at similar
time from seroconversion which may explain the relation-
ship between age and disease progression [57,119]. How-
ever, age disparities seem to diminish with HAART
treatment; CD4 counts and HIV-RNA levels becoming
more useful prognostic indicators [119]. It appears that
the age effect seen on HAART treatment is closer to the
natural effect of aging rather than the pre-treatment, HIV-
related increase in mortality, suggesting that HAART
attenuates the effect of age at seroconversion on HIV dis-
ease progression [120].
Gender
Mean HIV-RNA has been found to vary between men and
women for given CD4 count strata [107,121-123]. Low
levels of CD4+ T-cells (<50 cells/mm3) are associated with
higher mean HIV-RNA in women (of the order of 1.3
log10copies/mL) than in men within the same CD4 countAIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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stratum. Conversely, at higher CD4+ T-cell levels (>350
cells/mm3), mean HIV-RNA has been noted to be 0.2–0.5
log10copies/mL lower in women [124]. Despite HIV-RNA
variation, disease progression has not been seen to differ
between the genders for given CD4 counts [121,124,125].
On this basis, the current DHHS Guidelines for the use of
Antiretroviral Drugs in HIV-1 Infected Adults and Adolescents
state that there is no need for sex-specific treatment guide-
lines for the initiation of treatment given that antiretrovi-
ral therapy initiation is guided primarily by CD4 count
[6].
Mode of transmission
Comparing disease progression rates between transmis-
sion risk groups has led to conflicting findings. An early
study found significantly faster progression amongst
homosexuals than heterosexuals [126]. However, more
recent studies analysing much larger cohorts reported no
difference in disease progression rates following adjust-
ment for age and exclusion of Kaposi's sarcoma as an
AIDS defining illness [62,127,128]. Prins et al. [127]
noted that injecting drug users have a very high other-
cause mortality rate that could confound results failing to
take this into account.
The CASCADE collaboration [120] examined the change
in morbidity and mortality between the pre- and post-
HAART periods. They found a reduction in mortality in
the post-HAART era amongst homosexual and heterosex-
ual risk groups but no such change in injecting drug users.
This apparently higher risk of death than other groups
may be related to poor therapy adherence, less access to
HAART and the higher rate of co-morbid illnesses such as
Hepatitis C. Other factors may have a larger role to play in
clinical deterioration than the mode of transmission.
Psychosocial factors
Understanding the interaction between physical and psy-
chosocial factors in disease progression is important to
maximise holistic care for the patient. Several studies have
found significant relationships between poorer clinical
outcome and lack of satisfaction with social support,
stressful life events, depression and denial-based coping
strategies [129-132]. Other studies have found strong cor-
relations between poorer adherence to therapy and
depression, singleness and homelessness [106,133].
Patient management should include consideration of the
psychosocial context and aim to provide assistance in
problem areas.
Resource limited settings
The three elements of host, immunological and virologi-
cal factors obviously synergise to influence the progres-
sion of HIV infection, however, a few additional factors
may hold prognostic value. While CD4 count and HIV-
RNA are the gold standard markers for disease monitor-
ing, when measurement of these parameters is not possi-
ble surrogate markers become important. Markers
investigated for their utility as simple markers for disease
progression in resource-limited settings include delayed
type hypersensitivity responses (DTH), total lymphocyte
count (TLC), haemoglobin and body mass index (BMI).
Delayed type hypersensitivity
Mediated by CD4+ T-lymphocytes, DTH-type responses
give an indication of CD4+ T-cell function in vivo. It has
been shown that DTH responses decline in parallel with
CD4+ T-cells resulting in a corresponding increase in mor-
tality [134,135]. Failure to respond to a given number of
antigens has been suggested as a marker for the initiation
of ART in resource-limited settings [135,136].
Improved DTH responses have been noted with ART,
although the degree of improvement appears dependent
on the CD4+ nadir prior to HAART initiation [137-139].
This holds implications for the timing of initiation of
treatment, as delayed treatment and hence low nadir CD4
counts may cause long-term immune deficits [139]. There
is a need for further research in resource-limited settings
to determine the utility of DTH testing as both a marker
for HAART initiation and a means of monitoring its effi-
cacy.
Total lymphocyte count
Another marker available in resource-limited countries,
total lymphocyte count (TLC), has been investigated as an
alternative to CD4+ T-cell count. Current WHO guidelines
recommend using 1200 cells/mm3 or below as a substi-
tute marker for ART initiation in symptomatic patients
[140]. Evidence for the predictive worth of this TLC level
is encouraging, with several large studies confirming the
significant association between a TLC of <1200 cells/mm3
and subsequent disease progression or mortality
[135,141,142]. Others propose that rate of TLC decline
should be used in disease monitoring as a rapid decline
(33% per year) precedes the onset of AIDS by 1–2 years
[142,143]. Disappointingly, there is generally a poor cor-
relation between TLC and CD4 count at specific given val-
ues.
While TLC measurement has been validated as a means of
monitoring disease progression in ART-naïve patients, its
use for therapeutic monitoring is questionable and not
recommended [49,144-146].
Body mass index
The body mass index (BMI) is a simple and commonly
used measure of nutritional status. Its relationship to sur-
vival in HIV infection is important for two main reasons.
Firstly, 'wasting syndrome' (>10% involuntary weight lossAIDS Research and Therapy 2007, 4:11 http://www.aidsrestherapy.com/content/4/1/11
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in conjunction with chronic diarrhoea and weakness, +/-
fever) is considered an AIDS defining illness according to
the CDC classification of disease [1]. Secondly, the ease of
measurement of this parameter makes it potentially
highly useful as a marker for the initiation of ART in
resource limited countries.
Like TLC, long-term monitoring of BMI is predictive of
disease progression. A rapid decline has been noted in the
6 months preceding AIDS although the sensitivity of this
measure was only 33% [145,146]. A baseline BMI of
<20.3 kg/m2 for men and <18.5 kg/m2 for women is pre-
dictive of increased mortality, even in racially diverse
cohorts, with a BMI of 17–18 kg/m2 and <16 kg/m2 being
associated with a 2-fold and 5-fold risk of AIDS respec-
tively [147-149].
In combination with other simple markers such as hae-
moglobin, clinical staging and TLC, a BMI <18.5 kg/m2
shows similar utility to CD4 count and HIV-RNA based
guidelines for the initiation of HAART [150,151]. A sus-
tained BMI <17 kg/m2 6 months after HAART initiation
has been associated with a two-fold increase in risk of
death [152].
As can be seen, measurement of the body mass index is a
simple and useful predictor of disease progression. A BMI
of <18.5 kg/m2 was consistently strongly associated with
increased risk of disease progression and may prove to be
a valuable indicator of the need for HAART.
Haemoglobin
Haemoglobin levels reflect rapidity of disease progression
rates and independently predict prognosis across demo-
graphically diverse cohorts [151,153]. Rates of haemo-
globin decrease also correlate with falling CD4 counts
[135,141].
There have been suggestions that increases in haemo-
globin are predictive of treatment success when combined
with a TLC increase [143]. While racial variation in nor-
mal haemoglobin ranges and the side effects of antiretro-
viral agents such as zidovudine on the HIV infected bone
marrow must be taken into account [144], monitoring
haemoglobin levels shows utility in predicting disease
progression both before and following HAART initiation.
Conclusion
The evolution of HIV infection from the fusion of the first
virion with a CD4+ T-cell to AIDS and death is influenced
by a multitude of interacting factors. However, in gaining
an understanding of the prognostic significance of just a
few of these elements it may be possible to improve the
management and long-term outcome for individuals.
Host factors, although unalterable, remain important in
considering the prognosis of the patient and guiding ther-
apeutic regimens. Furthermore, research into host-virus
interactions has great potential to enhance the develop-
ment of new therapeutic strategies.
Immunological parameters such as levels of CD38 expres-
sion and the diversity of HIV-specific cytotoxic lym-
phocyte responses allow insight into the levels of
autologous control of the virus. Virological monitoring,
including drug resistance surveillance, will continue to
play a considerable role in the management of HIV infec-
tion. Additionally, as access to antiretroviral therapy
improves around the world, the utility of, and need for,
low-cost readily available markers of disease is evident. As
with any illness of such magnitude, it is clear that a multi-
tude of factors must be taken into account in order to
ensure optimum quality of life and treatment results.
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Appendix 1
i The "Concerted Action of Seroconversion to AIDS and
Death in Europe" (CASCADE) collaboration includes
cohorts in France, Germany, Italy, Spain, Greece, Nether-
lands, Denmark, Norway, UK, Switzerland, Australia and
Canada
ii  The "TREAT Asia HIV Observational Database"
(TAHOD) database contains observational information
collected from 11 sites in the Asia-Pacific region, encom-
passing groups from Australia, India, the Philippines,
Malaysia, China, Singapore and Thailand.
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